Home / Care Tools / Research / Care Tools Research

Care Tools Research

Since DM1-related loss of muscle mass confounds a common biomarker of kidney dysfunction, creatinine levels, serum cystatin C provides a superior measure of renal dysfunction for both patient management and clinical trials.

 

A recent study corroborated increased susceptibility to cancer in DM1, for women in particular, and linked the elevated risk to depressed levels of a tumor suppressor microRNA (miRNA). 

Dr. Guillaume Bassez and a large team in France and Canada recently published an analysis of gender and its impact on the DM1 phenotype. Read about their findings in this article.

Several scientists have published the results of important DM research. Dr. Katharine Hagerman, PhD, Research Assistant at Stanford University, has provided MDF with lay summaries of some of this research.

Dr. John Vissing and his colleagues at the University of Copenhagen recently tracked a group of 68 adults with myotonic dystrophy type 1 (DM1), measuring their endocrine function change over 8 years.

Insulin Resistance

Insulin resistance can be managed in the following ways:

Insulin Resistance

Diagnosis of insulin resistance in individuals with myotonic dystrophy typically involves blood tests that measure:

Click here for a print-ready version of this page. 

Partners

© Myotonic Dystrophy Foundation. All rights reserved.